Article
The Development of FLT3 Inhibitors in Acute Myeloid Leukemia.
Hematology/oncology clinics of North America - 1 Aug 2017
Garcia Jacqueline S, Stone Richard M
Abstract excerpt
FLT3 mutations, generally associated with a poor prognosis, are found in approximately one-third of patients with acute myeloid leukemia (AML) and represent an attractive therapeutic target. FLT3 inhibitors undergoing clinical evaluation include first-generation relatively non-specific small mole...
Topics
- Antineoplastic Agents
- Antineoplastic Combined Chemotherapy Protocols
- Clinical Trials as Topic
- Drug Discovery
- Drug Resistance, Neoplasm
- Humans
- Leukemia, Myeloid, Acute
- Mutation
- Prognosis
- Protein Kinase Inhibitors
- Recurrence
- Signal Transduction
- Treatment Outcome
- fms-Like Tyrosine Kinase 3